Osteoporosis Treatment Market Report 2025

The osteoporosis treatment market size has grown steadily in recent years. It will grow from $13.96 billion in 2024 to $14.62 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to aging population demographics, hormone replacement therapies, calcium and vitamin d supplementation, increased diagnostic tools, integration of digital health solutions.

The osteoporosis treatment market size is expected to see strong growth in the next few years. It will grow to $17.84 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rise in sedentary lifestyles, rising prevalence of secondary osteoporosis, virtual bone fracture clinics, gene therapy for osteoporosis, increased focus on men's bone health. Major trends in the forecast period include advancements in biologics, integration of artificial intelligence, blockchain in bone health records, integration of machine learning.

The rising prevalence and incidence of osteoporosis are anticipated to drive the growth of the osteoporosis treatment market in the future. Osteoporosis is a bone disease that occurs when there are changes in bone strength and composition, or when there is a decline in bone mass and mineral density. Most osteoporosis medications work by slowing the deterioration of bones, while hormone-based treatments, such as estrogen, can help maintain bone density, particularly when started shortly after menopause. For example, in May 2022, Amgen, a US-based biopharmaceutical company, projected that the annual number of osteoporosis-related fractures could rise by 68%, reaching 3.2 million by 2040. Additionally, in April 2022, the National Library of Medicine reported that approximately 549,000 new fragility fractures are recorded annually in the UK, with one-third of these cases occurring in men. Due to the aging population, this figure is expected to increase by 19.6% by 2030. Consequently, the growing prevalence and incidence of osteoporosis are fueling the expansion of the osteoporosis treatment market.

The growth of the osteoporosis treatment market is fueled by the escalating healthcare expenditures. Healthcare expenditures encompass the total spending on healthcare services and products within a specific timeframe. Osteoporosis treatment contributes significantly to the rising healthcare costs, covering expenses for diagnostic tests, medications, rehabilitation services, and potential surgeries. In November 2022, the CIHI projected a 0.8% increase in total health spending in Canada, from $328 billion in 2021 to $331 billion in 2022, underscoring the market's expansion facilitated by the surge in healthcare expenditures.

Major companies in the osteoporosis treatment market are concentrating on the development of advanced injectable therapies to maintain their competitive edge. Injectable osteoporosis treatments are administered through injections to help prevent bone loss and lower fracture risk in individuals with osteoporosis. These treatments provide a direct approach to improving bone density and enhancing skeletal health. For example, in November 2023, Apotex Corp., a Canada-based pharmaceutical company, introduced Teriparatide Injection. This pre-filled pen is designed for single-patient use in the treatment of osteoporosis, featuring a concentration of 250 mcg/mL and offering 28 daily doses of 20 mcg each per pen. This product aims to improve access to affordable treatment for approximately 10 million Americans affected by osteoporosis. Its development highlights Apotex's commitment to producing complex generic medications, ensuring that patients have access to high-quality treatment.

Leading companies in the osteoporosis treatment market are strategically focusing on the development of derivative capsules, particularly those containing vitamin D3, to attain a competitive advantage. In December 2022, Chugai Pharmaceutical Co., Ltd., based in Tokyo, collaborated with Towa Pharmaceutical, a Japan-based counterpart, to launch 'Edirol Tablets 0.5 µg/0.75 µg.' These capsules, featuring an active vitamin D3 derivative, are tailored for the treatment of osteoporosis. Specifically designed to enhance bone and calcium metabolism, Edirol Tablets aim to reduce vertebral fractures and increase bone mineral density, exemplifying the companies' commitment to cutting-edge solutions.

In May 2023, Abiogen Pharma, an Italy-based specialist in osteoarticular and bone metabolism diseases, acquired a 97.09% stake in EffRx Pharmaceuticals. This strategic acquisition, conducted for an undisclosed amount, serves to strengthen Abiogen Pharma's global presence and underscores its dedication to bone health and rare diseases. EffRx Pharmaceuticals, headquartered in Switzerland, possesses a portfolio that includes products for the treatment of postmenopausal osteoporosis, aligning with Abiogen Pharma's broader objectives in the field.

Major companies operating in the osteoporosis treatment market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck and Co Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline Pharmaceutical Ltd., Takeda Pharmaceutical Company, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Corporation, AstraZeneca Plc., Viatris Inc., Teva Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Ltd, Dr. Reddy's Laboratories, Gedeon Richter Plc., Celltrion Inc., Luye Pharma Group, Ligand Pharmaceuticals Incorporated, Radius Health Inc., Haoma Medica Ltd., EffRx Pharmaceuticals SA.

North America was the largest region in the osteoporosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteoporosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Osteoporosis treatment encompasses medical interventions designed to manage and improve the condition of osteoporosis. This bone disease occurs when there is a decline in bone mass and mineral density, or when the composition and strength of bones change. The primary goals of osteoporosis treatment are to stop bone deterioration, reduce the risk of fractures, and enhance overall bone health.

Key pharmaceuticals involved in osteoporosis treatment include bisphosphonates, calcitonin, hormone therapy, selective estrogen receptor modulators (SERMs), parathyroid hormone-related protein (PTHrP) analog, and rank ligand (RANKL) inhibitor. Bisphosphonates, recognized for their efficacy in relieving bone discomfort associated with certain cancers and hypercalcemia, are pivotal in preventing osteoporotic fractures. These medications can be administered orally, through injections, and other modalities, with distribution channels spanning hospitals, retail pharmacies, stores, and online pharmacies.

The osteoporosis treatment research report is one of a series of new reports that provides osteoporosis treatment market statistics, including the osteoporosis treatment industry's global market size, regional shares, competitors with osteoporosis treatment market share, detailed osteoporosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis treatment industry. This osteoporosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteoporosis treatment market consists of revenues earned by entities by providing osteoporosis services such as physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteoporosis treatment market also includes sales of alendronate, risedronate, Ibandronate, and zoledronic acid. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.